Lilly Unveils Landmark Phase 3 Data for Foundayo and Retatrutide at ADA 2026
INDIANAPOLIS, May 28, 2026 Eli Lilly and Company has announced a major slate of scientific presentations for the American...
Orforglipron
Advertisement
Lilly’s Foundayo Shows Strong Weight Loss in Seniors
Indianapolis, Indiana, USA – May 22, 2026 Eli Lilly and Company announced new clinical analysis from the Phase 3...
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
Lilly Foundayo Shows Strong Phase 3 Diabetes Results
INDIANAPOLIS, April 16, 2026 Eli Lilly and Company announced positive results from its ACHIEVE-4 Phase 3 clinical trial, demonstrating...
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
Advertisements
FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Lilly Invests $6.5 B to Build API Plant in Houston
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
Lilly’s Oral GLP-1 Outperforms Oral Semaglutide in Phase 3 Trial
INDIANAPOLIS, Sept. 17, 2025 – Eli Lilly and Company (NYSE: LLY) announced today that its investigational oral GLP-1 receptor...
Advertisement
